Singapore Pharmaceutical Market by Product Type, Distribution Channel, End User 2024-2032
                     Singapore 
Pharmaceutical Market 
Research and Forecast 
Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
A c c o r d i n g  t o  t h e  l a t e s t  r e p o r t  b y  I M A R C  G r o u p ,  t i t l e d  " S i n g a p o r e  P h a r m a c e u t i c a l  M a r k e t :  
I n d u s t r y  T r e n d s ,  S h a r e ,  S i z e ,  G r o w t h ,  O p p o r t u n i t y  a n d  F o r e c a s t  2 0 2 4 - 2 0 3 2 , "  t h e  S i n g a p o r e  
p h a r m a c e u t i c a l  m a r k e t  s i z e  i s  p r o j e c t e d  t o  e x h i b i t  a  g r o w t h  r a t e  ( C A G R )  o f  5 . 7 0 %  d u r i n g  2 0 2 4 -
2 0 3 2 .
S i n g a p o r e  P h a r m a c e u t i c a l  Ma r k e t  T r e n d s  a n d  D r i v e r s :
Report R i s e  o f  B i o l o g i c s  a n d  B i os i m i l a r s :
T h e  S i n g a p o r e  p h a r m a c e u t i c a l  m a r k e t  i s  w i t n e s s i n g  a  s i g n i f i c a n t  s h i f t  t o w a r d s  b i o l o g i c s  a n d  
b i o s i m i l a r s ,  d r i v e n  b y  a d v a n c e m e n t s  i n  b i o t e c h n o l o g y  a n d  a  g r o w i n g  d e m a n d  f o r  p e r s o n a l i z e d  
Highlight and m e d i c i n e .  B i o l o g i c s ,  w h i c h  a r e  c o m p l e x  m o l e c u l e s  d e r i v e d  f r o m  l i v i n g  c e l l s ,  o f f e r  t a r g e t e d  t h e r a p i e s  f o r  c o n d i t i o n s  s u c h  a s  c a n c e r ,  a u t o i m m u n e  d i s e a s e s ,  a n d  g e n e t i c  d i s o r d e r s .  T h e  
S i n g a p o r e  g o v e r n m e n t ’ s  s u p p o r t  f o r  b i o p h a r m a c e u t i c a l  i n n o v a t i o n ,  t h r o u g h  i n i t i a t i v e s  l i k e  t h e  
Description B i o m e d i c a l  S c i e n c e s  I n d u s t r y  P a r t n e r s h i p  O f f i c e  ( B M S  I P O ) ,  h a s  e n c o u r a g e d  b o t h  l o c a l  a n d  i n t e r n a t i o n a l  c o m p a n i e s  t o  i n v e s t  i n  b i o l o g i c s  r e s e a r c h  a n d  d e v e l o p m e n t .  B i o s i m i l a r s ,  w h i c h  a r e  
s i m i l a r  t o  e x i s t i n g  b i o l o g i c  d r u g s ,  a r e  g a i n i n g  t r a c t i o n  a s  c o s t - e f f e c t i v e  a l t e r n a t i v e s ,  e s p e c i a l l y  i n  
a  m a r k e t  w h e r e  h e a l t h c a r e  c o s t s  a r e  a  m a j o r  c o n c e r n .  R e g u l a t o r y  b o d i e s  i n  S i n g a p o r e ,  s u c h  a s  
t h e  H e a l t h  S c i e n c e s  A u t h o r i t y  ( H S A ) ,  h a v e  s t r e a m l i n e d  t h e  a p p r o v a l  p r o c e s s  f o r  b i o s i m i l a r s ,  
e n s u r i n g  t h a t  t h e y  m e e t  r i g o r o u s  s a f e t y  a n d  e f f i c a c y  s t a n d a r d s .  T h e  i n c r e a s i n g  a d o p t i o n  o f  
b i o l o g i c s  a n d  b i o s i m i l a r s  i s  a l s o  f u e l e d  b y  t h e  g r o w i n g  p r e v a l e n c e  o f  c h r o n i c  d i s e a s e s  a n d  t h e  
n e e d  f o r  m o r e  e f f e c t i v e  a n d  s u s t a i n a b l e  t r e a t m e n t  o p t i o n s .  T h i s  t r e n d  i s  e x p e c t e d  t o  c o n t i n u e ,  
d r i v e n  b y  o n g o i n g  r e s e a r c h  a n d  t h e  e n t r y  o f  n e w  p l a y e r s  i n  t h e  b i o l o g i c s  s p a c e ,  t h e r e b y  
e n h a n c i n g  t h e  t h e r a p e u t i c  l a n d s c a p e  a n d  e x p a n d i n g  m a r k e t  o p p o r t u n i t i e s .
Digi ta l  Hea l th  Integrat ion and E-Pharmacy Expans ion:
Dig i t a l  he a l t h  t echn o log ie s  a nd  e - pha r m a cy  p la t f o r m s  a r e  r ev o lu t i o n i z ing  t he  
pha r m ac eu t i ca l  l and scap e  i n  S inga po r e .  The  i n t eg r a t i on  o f  d ig i t a l  h ea l t h  t oo l s ,  s uch  
as  t e lem e d ic ine ,  e lec t r on i c  hea l t h  r ec o r ds  ( EHR s) ,  a nd  m ob i l e  he a l t h  app l i ca t i o ns ,  
i s  enh anc in g  pa t i en t  ca r e  an d  s t r ea m l in i ng  pha r m ace u t i ca l  s e r v i ce s .  Te l em ed i c ine  
has  see n  a  s ubs t a n t i a l  i nc r ease  i n  adop t i on ,  pa r t i cu la r l y  d u r i ng  t h e  CO VI D - 19  
pand em ic ,  enab l i n g  p a t i en t s  t o  c onsu l t  w i t h  hea l t hca r e  p r o f ess iona l s  r e m o t e l y  a nd  
acce ss  m e d ica t i o ns  con ven ien t l y .  E - pha r m acy  p l a t f o r m s  a r e  g a in ing  p opu la r i t y  as  
Report t hey  o f f e r  hom e  de l i ve r y  se r v i ces ,  ens u r ing  t ha t  pa t i e n t s  r ece i v e  t he i r  m ed ica t io ns  
p r om p t l y  w i t hou t  t h e  n eed  t o  v is i t  phys i ca l  pha r m ac ie s .  The se  p la t f o r m s  a l so  
Highlight and p r ov ide  va lu e- adde d  se r v ic es  such  as  m ed ica t i on  r em inde r s ,  on l i ne  consu l t a t i o ns ,  and  pe r sona l i zed  hea l t h  adv i ce .  Th e  S ing apo r e  g ove r nm en t ’ s  p ush  t ow ar ds  a  Sm ar t  
Na t i o n  and  t he  i nc r e as ing  pen e t r a t i on  o f  i n t e r ne t  an d  s m ar t phon e  us age  f u r t he r  
Description sup po r t  t he  g r ow t h  o f  d ig i t a l  hea l t h  so l u t i ons .  Add i t i ona l l y ,  co l l abo r a t i on s  be t w een  pha r m ac eu t i ca l  c om p an ies  a nd  t e ch  f i r m s  a r e  l ead in g  t o  i nnova t i ve  so l u t i ons  t ha t  
im p r ove  m ed ica t io n  a dhe r ence ,  pa t i en t  en gagem en t ,  an d  ove r a l l  he a l t hc a r e  
ou t c om es .  The  sh i f t  t ow ar ds  d ig i t a l  hea l t h  an d  e - p ha r m acy  n o t  on l y  enhan ces  
acce ss ib i l i t y  an d  co nv en ie nce  f o r  pa t i en t s  bu t  a l s o  he lps  i n  be t t e r  m anage m en t  o f  
hea l t hca r e  r eso u r ces  and  da t a ,  c on t r i bu t i ng  t o  t h e  o ve r a l l  e f f i c i en cy  o f  t he  
hea l t hca r e  sy s t em .
Reque st  f o r  a  PDF  sam pl e  o f  t h i s  re por t :  
h t t p s : / / www. im ar c g r ou p . com / s in gapo r e - pha r m ac eu t i ca l - m ar ke t / r eq ues t sam p le
Report Description
Singapore  Pharmaceut ica l  Market  Trends:
The  S ingapore  pharmaceut i ca l  marke t  i s  d r i ven  by  seve ra l  key  fac t o r s ,  i nc lud ing  the  coun t ry ' s  r obus t  hea l t hca re  
in f ras t ruc tu re ,  gove rnment  suppor t  f o r  b iomed ica l  research ,  and  a  s t ra teg ic  f ocus  on  innova t i on  and  techno logy .  
S ingapore ' s  gove rnment  has  inves ted  heav i l y  in  t rans fo rm ing  the  coun t r y  in to  a  b iomed ica l  hub  th rough  in i t i a t i ves  l i ke  
the  Research ,  I nnovat ion  and  En te rp r i se  2020  (R I E2020)  p lan ,  wh ich  a l loca tes  subs tan t ia l  f und ing  fo r  sc ien t i f i c  
research .  Add i t i ona l l y ,  t he  p resence o f  l ead ing  g loba l  pha rmaceu t i ca l  compan ies  and  research  i ns t i t u t ions  in  
S ingapore  f os te rs  a  conduc ive  env i r onment  f o r  pha rmaceu t i ca l  advancemen ts .  
The  count ry ' s  s t ra teg i c  loca t ion  in  As ia  a l so  makes  i t  an  a t t r ac t i ve  hub  fo r  c l i n i ca l  t r i a l s  and  pharmaceu t i ca l  
manu fac t u r ing ,  benef i t i ng  f rom e f f i c ien t  r egu la to ry  f r am eworks  and s t r ong  in te l lec t ua l  p roper t y  p ro t ec t i ons .  W i t h  an  
ag ing  popu la t ion  and  r i s ing  p reva lence  o f  chron ic  d iseases ,  t he re  i s  an  i nc reas ing  demand f o r  innova t i ve  and h igh-
qua l i t y  pha rmaceut i ca l s .  Moreover ,  S ingapore 's  comm i tment  t o  ma in ta in ing  h igh  s t andards  in  hea l t hca re  serv i ces  and  
i t s  p roac t i ve  approach to  hea l t hca re  cha l lenges  fu r t her  enhance i t s  marke t  a t t rac t i veness .
Vi ew Report  TOC,  F igures and  Tab les :  h t tps: / / www. i marcgroup .com/s ingapore-pharmaceut ica l -market
Type Insights:
• Pharmaceut ical  Drugs
o Cardiovascular Drugs
o Dermatology Drugs
o Gastrointest inal  Drugs
o Genito-Ur inary Drugs
o Hematology Drugs
Report o Ant i- Infect ive Drugs
Segmentation o Metabol ic Disorder Drugs
o Musculoskeletal  Disorder Drugs
o Central  Nervous System Drugs
o Oncology Drugs
o Ophthalmology Drugs
o Respiratory Diseases Drugs
• Biologics
o Monoclonal Antibodies (MAbS)
o Therapeutic Proteins
o Vaccines
Nature Insights:
• Organic
• Conventional
Report 
Segmentation Regional Insights:
• North-East
• Central
• West
• East
• North
How has the Singapore pharmaceutical market 
performed so far and how will it perform in the coming 
years?
What has been the impact of COVID-19 on the 
Singapore pharmaceutical market?
What is the breakup of the Singapore pharmaceutical 
Key market on the basis of type?
Questions What is the breakup of the Singapore pharmaceutical market on the basis of nature?
Answered in 
What are the various stages in the value chain of the 
the Report Singapore pharmaceutical market?
What are the key driving factors and challenges in the 
Singapore pharmaceutical?
What is the structure of the Singapore pharmaceutical 
market and who are the key players?
What is the degree of competition in the Singapore 
pharmaceutical market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
        2 . 4 . 1     B o t t o m - U p  A p p r o a c h
Table of         2 . 4 . 2     T o p - D o w n  A p p r o a c h    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     S i n g a p o r e  P h a r m a c e u t i c a l  M a r k e t  –  I n t r o d u c t i o n
4 . 1     O v e r v i e w
Contents 4 . 2     M a r k e t  D y n a m i c s4 . 3     I n d u s t r y  T r e n d s
4 . 4     C o m p e t i t i v e  I n t e l l i g e n c e
5     S i n g a p o r e  P h a r m a c e u t i c a l  M a r k e t  L a n d s c a p e
5 . 1     H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
5 . 2     M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
6     S i n g a p o r e  P h a r m a c e u t i c a l  M a r k e t  -  B r e a k u p  b y  T y p e
6 . 1     P h a r m a c e u t i c a l  D r u g s
6 . 1 . 1     O v e r v i e w
6 . 1 . 2     H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
6 . 1 . 3     M a r k e t  S e g m e n t a t i o n
6 . 1 . 3 . 1     C a r d i o v a s c u l a r  D r u g s
6 . 1 . 3 . 2     D e r m a t o l o g y  D r u g s
6 . 1 . 3 . 3     G a s t r o i n t e s t i n a l  D r u g s
6 . 1 . 3 . 4     G e n i t o - U r i n a r y  D r u g s
6 . 1 . 3 . 5     H e m a t o l o g y  D r u g s
6 . 1 . 3 . 6     A n t i - I n f e c t i v e  D r u g s
       
6 .1 . 3 . 7     M e t a b o l i c  D i s o r d e r  D r u g s
6 .1 . 3 . 8     M u s c u l o s k e l e t a l  D i s o r d e r  D r u g s
6 .1 . 3 . 9     C e n t r a l  N e r v o u s  S y s te m D r u g s
6 .1 . 3 . 1 0     O n c o l o g y  D r u g s
6 .1 . 3 . 1 1     O p h t h a l m o l o g y  D r u g s
6 .1 . 3 . 1 2     R e s p i r a t o r y  D i s e a s e s  D r u g s
6 .1 . 4     Ma r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
6 .1 . 5     Ma r k e t  B r e a k u p  b y  N a t u r e
6 .2     B i o l o g i c s  
6 .2 . 1     Ov e r v i e w
Table of 6 .2 . 2     H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )6 .2 . 3     Ma r k e t  S e g m e n ta t i o n
6 .2 . 3 . 1     M o n o c l o n a l  A n t i b o d i e s  ( M A b S )
6 .2 . 3 . 2     T h e r a p e u t i c  P r o te i n s
Contents 6 .2 . 3 . 3     V a c c i n e s
6 .2 . 4     Ma r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
6 .2 . 5     Ma r k e t  B r e a k u p  b y  N a t u r e
6 .3     A t t r a c t i v e  I n v e s tm e n t  P r o p o s i t i o n  b y  T y p e
7     S in g a p or e  P h a r m a c e u t ic a l  M a r k e t  -  B r e a k u p  b y  N a t u r e
7 .1     O r g a n i c
7 .1 . 1     Ov e r v i e w
7 .1 . 2     H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
7 .1 . 3     Ma r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
7 .1 . 4     Ma r k e t  B r e a k u p  b y  T y p e     
7 . 2     C o n v e n t i o n a l
7 .2 . 1     Ov e r v i e w
7 .2 . 2     H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
F o r  m o r e  i n f o r m a t io n ,  v i s i t :  
ht tps : / /www. imarcgroup .com/s ingapore -pharmaceut i ca l -mar
ket / t oc
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: